Jean-Michel Halimi,Pantelis Sarafidis,Michel Azizi,Grzegorz Bilo,Thilo Burkard,Michael Bursztyn,Miguel Camafort,Neil Chapman,Santina Cottone,Tine de Backer,Jaap Deinum,Philippe Delmotte,Maria Dorobantu,Michalis Doumas,Rainer Dusing,Béatrice Duly-Bouhanick,Jean-Pierre Fauvel,Pierre Fesler,Zbigniew Gaciong,Eugenia Gkaliagkousi,Daniel Gordin,Guido Grassi,Charalampos Grassos,Dominique Guerrot,Justine Huart,Raffaele Izzo,Fernando Jaén Águila,Zoltán Járai,Thomas Kahan,Ilkka Kantola,Eva Kociánová,FlorianP. Limbourg,Marilucy Lopez-Sublet,Francesca Mallamaci,Athanasios Manolis,Maria Marketou,Gert Mayer,Alberto Mazza,IainM. MacIntyre,Jean-Jacques Mourad,Maria Lorenza Muiesan,Edgar Nasr,Peter Nilsson,Anna Oliveras,Olivier Ormezzano,Vitor Paixão-Dias,Ioannis Papadakis,Dimitris Papadopoulos,Sabine Perl,Jorge Polónia,Roberto Pontremoli,Giacomo Pucci,Nicolás Roberto Robles,Sébastien Rubin,Luis Miguel Ruilope,Lars Christian Rump,Sahrai Saeed,Elias Sanidas,Riccardo Sarzani,Roland Schmieder,François Silhol,Sekib Sokolovic,Marit Solbu,Miroslav Soucek,George Stergiou,Isabella Sudano,Ramzi Tabbalat,Istemihan Tengiz,Helen Triantafyllidi,Konstontinos Tsioufis,Jan Václavík,Markus van der Giet,Patricia Van der Niepen,Franco Veglio,RetoM. Venzin,Margus Viigimaa,Thomas Weber,Jiri Widimsky,Gregoire Wuerzner,Parounak Zelveian,Pantelis Zebekakis,Stephan Lueders,Alexandre Persu,Reinhold Kreutz,Liffert Vogt

Abstract:Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70–95%]) than MRA (20% [10–30%]), SGLT2i (30% [20–50%]) or (GLP1-RA (10% [5–15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15–40%) vs 18% [10%–25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5–5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management. What is the context? Hypertension is a strong independent risk factor for development of chronic kidney disease (CKD) and progression of CKD to ESKD. Improved adherence to the guidelines in the treatment of CKD is believed to provide further reduction of cardiorenal events. European Society of Hypertension Excellence Centres (ESH-ECs) have been developed in Europe to provide excellency regarding management of patients with hypertension and implement guidelines. Numerous deficits regarding general practitioner CKD screening, use of nephroprotective drugs and referral to nephrologists prior to referral to ESH-ECs have been reported. In contrast, real-life management of these patients among ESH-ECs is unknown. Before implementation of strategies to improve guideline adherence in Europe, we aimed to investigate how patients with CKD are managed among the ESH-ECs. What is the study about? In this study, a survey was conducted in 2023 by the ESH to assess management of CKD patients referred to ESH-ECs. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed among their centres. What are the results? RAAS blockers are initiated in 90% of ESH-ECs in CKD patients, but the initiation of MRA and SGLT2i is less frequently done. Hyperkalemia is the main barrier for initiation or adequate dosing of RAAS blockade, and its most reported management was RAAS blockers dosage reduction. These findings will be crucial to implement strategies in order to improve management of patients with CKD and guideline adherence among ESH-ECs.

The Hypertension Excellence Centre programme of the European Society of Hypertension – current status, activities and reshaping for the future

Assessment and Management of Patients with Obesity and Hypertension in European Society of Hypertension Excellence Centres. A survey from the ESH Working Group on Diabetes and Metabolic Risk Factors.

ASSESSMENT AND MANAGEMENT OF PATIENTS WITH OBESITY AND HYPERTENSION IN EUROPEAN SOCIETY OF HYPERTENSION EXCELLENCE CENTRES. A SURVEY FROM THE ESH WORKING GROUP ON DIABETES AND META

Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney

HYPERTENSION MANAGEMENT OF CKD PATIENTS REFERRED TO HYPERTENSION EXCELLENCE CENTRES IN 27 COUNTRIES; ON BEHALF OF THE ESH HYPERTENSION AND KIDNEY WORKING GROUP

HYPERTENSIVE URGENCIES AND EMERGENCIES. A QUESTIONNAIRE AMONG EXCELLENCE CENTERS OF THE EUROPEAN SOCIETY OF HYPERTENSION

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.

Why were the 2023 Guidelines of the European Society of Hypertension not developed as Joint Guidelines together with the European Society of Cardiology?

A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension

World Heart Federation Roadmap for Hypertension – A 2021 Update

Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension

Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension

Editors' Commentary on the 2023 ESH Management of Arterial Hypertension Guidelines

2020 International Society of Hypertension global hypertension practice guidelines.

The need for a personalized "implementation hypertension" strategy to facilitate the implementation of the new European Society of Hypertension (2023), European Society of Cardiology (2024) and the upcoming Japanese Society of Hypertension (2025) hypertension guidelines in clinical practice

The Role of Exercise Blood Pressure in Hypertension: Measurement, Mechanisms and Management

Development of the certificate course in the management of hypertension in Africa (CCMH-Africa): proceedings of the first continental faculty meeting, Nairobi, Kenya, 25-26 February 2018

Perspectives on improving blood pressure control to reduce the clinical and economic burden of hypertension

The future of education in Preventive Cardiology. A Statement of the European Association of Preventive Cardiology (EAPC) of the ESC

[Progress in the treatment of hypertension]